GSK presented the data of Zejula, a PARP inhibitor, which improves PFS in women with first-line platinum responsive advanced ovarian cancer.

ESMO2019

Pfizer has presented ORAL shift study of Xeljanz XR in patients who have rheumatoid arthritis​

AbbVie has presented long term data of upadacitinib at EULAR 2019. The data was presented from the Phase 3 trials indicating the long term safety and efficacy of upadacitinib

EULAR 2019

AbbVie has presented two-year data of Skyrizi (risankizumab) showing complete clearance in patients suffering from plaque psoriasis. Skyrizi is indicated for the treatment of plaque psoriasis in adults and has recently received the approval from the European Medicines Agency.

ADA2019

Novartis has presented the clinical trial data of Kisqali in combination with endocrine therapy for the treatment of pre- and perimenopausal women with HR+/HER2- advanced or metastatic breast cancer​

Kite announced Yescarta data from ZUMA-1 study in patients suffering from relapsed or refractory large B-cell lymphoma.

Merck has presented the long term survival data of Keytruda in patients suffering from advanced non-small cell lung cancer. ​

AbbVie is presenting more than 40 clinical trial outcomes of its anticancer products for more than fifteen different cancers​

Amgen has presented the data of first KRASG12C inhibitor AMG 510 for patients suffering from solid tumors.

ASCO 2019

AbbVie has presented two-year data of Skyrizi (risankizumab) showing complete clearance in patients suffering from plaque psoriasis. Skyrizi is indicated for the treatment of plaque psoriasis in adults and has recently received the approval from the European Medicines Agency.

WCD 2019